Key terms
About ANVS
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ANVS news
Apr 16
12:00pm ET
Annovis Bio falls -9.6%
Apr 15
8:46am ET
Largest borrow rate increases among liquid names
Apr 12
8:46am ET
Largest borrow rate increases among liquid names
Apr 04
8:46am ET
Largest borrow rate increases among liquid names
Apr 03
8:46am ET
Largest borrow rate increases among liquid names
Apr 02
8:46am ET
Largest borrow rate increases among liquid names
Apr 02
6:25am ET
Buy Rating Reiterated for Annovis Bio Amid Anticipated Positive Trial Results for Alzheimer’s and Parkinson’s Treatments
Apr 01
8:16am ET
Annovis Bio announces publication on buntanetap
Mar 25
8:46am ET
Largest borrow rate increases among liquid names
Mar 22
10:00am ET
Annovis Bio falls -9.0%
Mar 21
3:10pm ET
Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbSci (ABSI)
Mar 21
7:40am ET
Analysts Are Bullish on These Healthcare Stocks: Insulet (PODD), Annovis Bio (ANVS)
Mar 21
6:31am ET
Analysts Are Bullish on Top Healthcare Stocks: Femasys (FEMY), BioNTech SE (BNTX)
Mar 20
4:52pm ET
Annovis Bio Promises Market-Impacting Information Release
Mar 20
12:00pm ET
Annovis Bio rises 30.0%
Mar 20
9:47am ET
Annovis Bio rises 8.7%
Mar 20
7:33am ET
Annovis Bio completes data cleaning for Phase II/III study of buntanetap
Mar 18
10:00am ET
Annovis Bio rises 9.1%
Feb 28
4:58am ET
Annovis Bio downgraded to Hold from Buy at Brookline
Feb 28
4:55am ET
Maintaining Hold on Annovis Bio Amid Phase 3 Parkinson’s Trial Concerns and Financial Uncertainties
Feb 27
8:45am ET
Largest borrow rate increases among liquid names
Feb 26
12:00pm ET
Annovis Bio falls -12.0%
Feb 20
8:45am ET
Largest borrow rate increases among liquid names
Feb 16
8:45am ET
Largest borrow rate increases among liquid names
Feb 15
1:35pm ET
Buy Rating Justified for Annovis Bio Amidst Promising Buntanetap Clinical Trials and Strong Commercial Prospects
Feb 15
1:30pm ET
Analysts Are Bullish on These Healthcare Stocks: Annovis Bio (ANVS), Alnylam Pharma (ALNY)
Feb 15
6:25am ET
Buy Rating on Annovis Bio Amid Anticipated Positive Outcomes for Buntanetap in AD and PD Trials
Feb 14
7:35am ET
Annovis announces last patient last visit in Phase II/III study of buntanetap
Feb 12
8:45am ET
Largest borrow rate increases among liquid names
Feb 08
8:45am ET
Largest borrow rate increases among liquid names
Feb 02
12:00pm ET
Annovis Bio falls -9.6%
May 04
4:30am ET
Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
Apr 28
12:30pm ET
Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
Apr 11
4:30am ET
Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
Mar 23
4:30am ET
Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
Mar 18
4:30am ET
Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022)
Mar 08
3:30am ET
Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022
Mar 03
3:30am ET
Annovis Bio to Present at the Cowen 42nd Annual Health Care Conference
Jan 25
4:00am ET
Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease
Jan 10
3:30am ET
Annovis Bio Enhances Leadership Team with Two Senior Appointments
Jan 05
3:30am ET
Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401
Jan 03
3:30am ET
Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences
ANVS Financials
Key terms
Ad Feedback
ANVS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ANVS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range